China
Africa
Explore chapters and articles related to this topic
Breast Cancer: Surgical Perspectives
Published in Raymond Taillefer, Iraj Khalkhali, Alan D. Waxman, Hans J. Biersack, Radionuclide Imaging of the Breast, 2021
Patricia J. Eubanks, Hernan I. Vargas, Stanley R. Klein
Without the use of genetic testing, the SSO position statement suggests that patients with a pedigree of first-degree relatives with premenopausal bilateral cancer should be offered prophylactic mastectomy. However, genetic testing should not be used as a criterion for recommendation of prophylactic mastectomy.
Neural Networks in Urologic Oncology
Published in Raouf N.G. Naguib, Gajanan V. Sherbet, Artificial Neural Networks in Cancer Diagnosis, Prognosis, and Patient Management, 2001
In 1998, Tewari et al. published an economically minded paper proposing the use of ANNs to increase the accuracy of clinical staging of CaP in patients with clinically organ confined disease [15]. This study used a probabilistic neural network with a genetic adaptive algorithm to find individual and overall smoothing factors and a dataset of 1200 patients. The inputs for this model were race, DRE finding, size of tumour on ultrasound, PSA, biopsy Gleason score, and biopsy staging information (number of positive biopsies, bilateral cancer, and perineural invasion). Outputs were margin status, seminal vesicle involvement, and lymph node metastasis. The accuracy and area under the receiver operating characteristics (ROC) curve were 76.7% and 0.7940, 73.2% and 0.804, 72.6% and 0.768 for margins, seminal vesicle and lymph nodes, respectively. Of note, the negative predictive values were 92%, 100%, and 98% for margins, seminal vesicle, and lymph nodes, respectively. As the authors point out, such high negative predictive values may make such a model an important screening tool avoiding further costly staging procedures.
Adverse health behaviours in long-term testicular cancer survivors: a Danish nationwide study
Published in Acta Oncologica, 2021
Michael Kreiberg, Mikkel Bandak, Jakob Lauritsen, Thomas Wagner, Josephine Rosenvilde, Mads Agerbaek, Lars Dysager, Cathrine Juel Lau, Klaus Kaae Andersen, Gedske Daugaard
Out of the 2572 TCS, we excluded patients with bilateral cancer (N = 81), those treated with high dose chemotherapy and stem cell transplant in first line (N = 11) and patients treated with more than one line of treatment (N = 85). These groups were excluded due to small group size and/or heterogeneous population characteristics, leaving 2395 TCS for analysis. Most patients with clinical stage I disease were treated with orchiectomy only and followed on a five-year surveillance programme (surveillance). Patients with disseminated disease were treated with orchiectomy and standard chemotherapy (BEP) or abdominal radiotherapy (RT) and these groups included both patients with disseminated disease at time of diagnosis and patients with initial clinical stage I disease and later relapse. Adjuvant RT was administered in a specific time period to patients with clinical stage I seminoma deemed high-risk (tumour size ≥ 6 cm) [17].
Are TRUS-guided prostate biopsies in clinical practice robust enough to make a correct assessment of the surgical strategy in prostatectomies? Poor correlation between preoperative prostate biopsies and postoperative specimens
Published in Scandinavian Journal of Urology, 2019
Pontus Nilsson, Peter Ströberg
The poor correlation between biopsies and PAD results after prostatectomy in our clinical setting is a matter for concern, particularly as a significant number of these deviations might have had a substantial clinical impact. If known prior to surgery, treatment strategies may have been different, leading to ultimately a better survival prognosis for these patients. Similar concerning results have been reported in other studies. A study analysing the diagnostic performance of 12-core biopsy in detecting significant prostate cancer concluded that approximately half of the significant cancers were not accurately detected [4]. Sinnott et al. [11] reported a discrepancy in prostate cancer localization between biopsy and prostatectomy specimens in patients with unilateral positive biopsy, it was concluded that 12-core biopsy is inadequate to identify candidates for organ-sparing therapy. Most men in this study had bilateral cancer at prostatectomy and tumours missed by biopsy were clinically significant in 40% of patients. Our study presents similar results, with 40% (39/98) of cases having the presence of unknown tumour on the contralateral side.
Quantitative sensory profiles of upper extremity chemotherapy induced peripheral neuropathy: Are there differences in sensory profiles for neuropathic versus nociceptive pain?
Published in Canadian Journal of Pain, 2019
Elizabeth Andersen Hammond, Marshall Pitz, Pascal Lambert, Barbara Shay
A total of 191 participant visits were included in this analysis. Table 1 shows the participant demographics including age, cancer stage, cancer side, type of surgery, adjuvant treatment, history of nerve entrapment or damage, and loss of shoulder range of motion (ROM) at baseline. Participants had a mean age of 61.5 (range 34–78). Seventeen (35.4%) participants were classified as stage I, 22 (45.8%) as stage II, and 9 (18.8%) as stage III. Nineteen (39.6) participants had right-sided breast cancer, 28 (58.3%) had left-sided breast cancer, and 1 (2.1%) had bilateral cancer. Ten (20.8%) participants received reconstructive surgery and 37 (77.1%) received radiation post-chemotherapy. Thirty (62.5%) participants received FECD and 18 (37.5%) received TC.